Saying shares of GeneDx skyrocketed in 2024 may be an understatement. As a leader in its market, upside is still a legitimate possibility for this name.
Kevin Feeley, the CHIEF FINANCIAL OFFICER of $WGS ($WGS), sold 263 shares of the company on 12-02-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 1.1% of...
Kevin Feeley, the CHIEF FINANCIAL OFFICER of $WGS ($WGS), sold 2,108 shares of the company on 11-22-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 8.4% of...
Cautious investors have long known that healthcare spending rises steadily regardless of the direction of the overall economy. It's considered a defensive sector, but it still contains stocks that can...
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Capitol Federal Financial, Inc. CFFN: This holding company for Capitol Federal Savings Bank has seen the Zacks Consensus Estimate...
Summary GeneDx Holdings Corp. offers AI-driven genomics-related diagnostic services, focusing on pediatrics, rare diseases, and hereditary cancer screening, with significant recent price appreciation....
/PRNewswire/ -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions and GeneDx (Nasdaq: WGS), a leader in...
A financial-engineering move about to be made by the company is an indication of some deep and challenging problems.
The potential of a reverse split concerned investors.